Aminobutane bisphosphonate

Aminobutane bisphosphonate 是一种克氏锥虫 (Trypanosoma cruzi) 法尼基焦磷酸合酶 (FPPS) 抑制剂,对克氏锥虫的 IC50 为 30.77 μM,可抑制细胞内无鞭毛体期克氏锥虫的增殖且对非感染性上鞭毛体期无活性,并可降低破骨细胞性骨吸收、类骨质表面积以及每毫米骨表面的破骨细胞数量,因此可用于美洲锥虫病 (恰加斯病) 和制动相关性骨丢失的研究。
产品编号: MS-W76420 CAS No.: 32545-60-1 分子式: C4H13NO6P2 分子量: 233.10
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Aminobutane bisphosphonate 是一种克氏锥虫 (Trypanosoma cruzi) 法尼基焦磷酸合酶 (FPPS) 抑制剂,对克氏锥虫的 IC50 为 30.77 μM,可抑制细胞内无鞭毛体期克氏锥虫的增殖且对非感染性上鞭毛体期无活性,并可降低破骨细胞性骨吸收、类骨质表面积以及每毫米骨表面的破骨细胞数量,因此可用于美洲锥虫病 (恰加斯病) 和制动相关性骨丢失的研究。

生物实验数据

生物活性 Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi; it inhibits the proliferation of intracellular amastigote-stage Trypanosoma cruzi while showing no activity against the non-infective epimastigote stage, and it reduces osteoclastic bone resorption, osteoid surface area, and the number of osteoclasts per millimeter of bone surface, making it useful for research on American trypanosomiasis (Chagas disease) and disuse-associated bone loss.
体外研究
(In Vitro)

Aminobutane bisphosphonate (Compound 8) 可抑制纯化的克氏锥虫法尼基焦磷酸合酶的活性,其 IC50 为 30.77 μM。
Aminobutane bisphosphonate (最高 100 μM) 在最高 100 μM 的浓度下不会抑制克氏锥虫上鞭毛体的增殖,其 IC50 > 100 μM。
Aminobutane bisphosphonate (85 μM) 仅能抑制 13%的克氏锥虫无鞭毛体增殖,其 IC50 > 85 μM。

体内研究
(In Vivo)

Aminobutane bisphosphonate (Compound 8) (0.01-1.0 mg P/kg;皮下注射;术前连续 2 天给药) 可呈剂量依赖性抑制雄性 Sprague-Dawley 大鼠制动诱导的骨丢失,其中 0.10 mg P per kg 剂量可在 20 天时消除完整肢体与制动肢体之间的骨小梁体积差异,并将股骨灰重/长度的百分比差异降至 7.0%。

Animal Model: Sprague-Dawley (male, 250-280 g, immobilization-induced bone loss via unilateral sciatic neuroctomy)
Dosage: 0.01 mg P per kg; 0.10 mg P per kg; 1.0 mg P per kg
Administration: s.c.; 2 consecutive days prior to surgery
Result: Increased femoral ash weight in both intact and immobilized limbs in a dose-dependent manner at 10 and 20 days post-surgery (p < 0.05) compared to vehicle controls.
Abolished the immobilization-induced decrease in femoral ash weight at 10 days with 0.10 mg P per kg dose.
Reduced the percentage difference in femoral ash weight/length between intact and immobilized limbs from 11.5% in vehicle controls to 7.0% with 0.10 mg P per kg and 4.8% with 1.0 mg P per kg at 20 days.
Reduced femoral length in both limbs from 36.6 mm to 35.6 mm (intact) and 36.4 mm to 35.6 mm (immobilized) at 20 days with 1.0 mg P per kg dose (p < 0.05).
Increased trabecular bone volume to 52.1% (intact) and 41.0% (immobilized) at 10 days with 0.10 mg P per kg dose, compared to 17.9% (intact) and 7.9% (immobilized) in vehicle controls (p < 0.05).
Increased trabecular bone volume in a dose-dependent manner at 20 days: 22.9% (intact) and 15.5% (immobilized) with 0.01 mg P per kg; 37.6% (intact) and 35.4% (immobilized) with 0.10 mg P per kg; 71.6% (intact) and 68.1% (immobilized) with 1.0 mg P per kg (all p < 0.05 vs vehicle).
Eliminated the difference in trabecular bone volume between intact and immobilized limbs at 20 days with 0.10 and 1.0 mg P per kg doses.
Reduced osteoclast number per mm trabecular surface in both limbs at 20 days with all doses compared to vehicle controls (p < 0.05), eliminating the difference between intact and immobilized limbs seen in vehicle controls.
Reduced eroded surface in both limbs at 20 days with 0.01 mg P per kg (12.1% intact, 12.3% immobilized) and 1.0 mg P per kg (16.1% intact, 15.8% immobilized), and in immobilized limbs with 0.10 mg P per kg (17.7%) compared to vehicle controls (p < 0.05).
Reduced osteoid surface to 0.4% (intact) and 0.1% (immobilized) at 10 days with 0.10 mg P per kg dose, compared to 6.0% (intact) and 2.4% (immobilized) in vehicle controls (p < 0.05).
Decreased osteoid surface in a dose-dependent manner at 20 days: 1.3% (intact) with 0.01 mg P per kg; 0.2% (intact) and 0.3% (immobilized) with 0.10 mg P per kg; 0.2% (intact) and 0.1% (immobilized) with 1.0 mg P per kg (all p < 0.05 vs vehicle).
Reduced mineral apposition rate in intact limbs by 14% (0.82 μm/day and 0.83 μm/day, respectively) with 0.10 and 1.0 mg P per kg doses compared to vehicle controls (0.97 μm/day; p < 0.05), but did not further reduce rates in immobilized limbs.

化学信息

分子量 233.10
分子式 C4H13NO6P2
CAS No. 32545-60-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础